摘要
目的:分析帕金森病患者应用普拉克索联合左旋多巴治疗后疗效。方法:采用随机数字表法将我院2017年1月至2018年6月期间收治的97例帕金森病患者分组,对照组48例给予左旋多巴0.25-0.5 g,Tid,口服治疗,每4 d增加0.125 g,每日最大剂量<3 g,共计3个月,观察组49例联合普拉克索0.375 mg分三次口服治疗,分别采用显色反应法、运动功能评分(Unified parkinson’s disease rating scale,UPDRS Ⅲ)检测两组患者治疗前后超氧化物歧化酶(Superoxide dismutase,SOD)、谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-Px)、过氧化氢酶(Catalase,CAT)及血浆谷胱甘肽(L-glutathione,GSH)水平及运动功能,对比治疗后临床疗效及治疗期间不良事件发生率。结果:观察组治疗后SOD、GSH-Px、CAT、GSH水平及临床疗效均高于对照组,UPDRS Ⅲ评分低于对照组(P<0.05),两组不良反应发生率无统计学差异(P>0.05)。结论:普拉克索联合左旋多巴能够有效控制帕金森病病情进展,改善患者运动功能,安全性高。
Objective:To evaluate the effects of pramipexole combined with levodopa in patients with Parkinson′s disease.Methods: All together 97 patients with Parkinson′s disease admitted to our hospital from January2017 to June2018 were randomly assigned to two groups.48 patients of the control group were orally given levodopa,while 49 patients of the observation group were orally given levodopa combined with pramipexole.Exercise function score (Unified Parkinson′s Disease Rating Scale,UPDRS III ,UPDRS III),superoxide dismutase (SOD),glutathione peroxidase (GSH-Px),and catalase (CAT) before and after treatment were measured and compared.The incidence of adverse events during treatment was also compared.Results: The levels of SOD,GSH-Px,CAT,and GSH of the observation group were higher than those of the control group.The UPDRS III score of the observation group was lower than that of the control group (P<0.05).The incidence of adverse reactions of the observation group was lower than that of the control group within 3 months.Conclusion: Pramipexole combined with levodopa can effectively inhibit the progression of Parkinson′s disease,improve the motor function of patients,and have fewer complications.
作者
崔金凤
常连选
晋红宾
Cui Jin-feng;Chang Lian-xuan;Jin Hong-bin(Qixian People′s Hospital,Department of Neurology,a ward,Henan Qixian 456750)
出处
《四川生理科学杂志》
2019年第3期210-212,共3页
Sichuan Journal of Physiological Sciences
关键词
普拉克索
左旋多巴
帕金森病
应激反应
Pramipexole
Levodopa
Parkinson′s disease
Stress response
